Furkan Bahar/X
Aug 3, 2026, 12:30
Furkan Bahar: Thrombotic and Hemorrhagic Risk Profiles in Advanced Melanoma – Targeted vs Immune Combination Therapies
Furkan Bahar, Research Fellow at Dana Farber, shared a post on X about a recent article he and his colleagues co-authored, published in RPTH, adding:
“Excited to share our new paper, published in Research and Practice in Thrombosis and Haemostasis!
We compared VTE and bleeding risk between BRAF/MEK inhibitors and ipilimumab/nivolumab combination therapy in patients with advanced melanoma.”
Title: Venous Thromboembolism and Bleeding in Advanced Melanoma: A Propensity-Matched Cohort Analysis Comparing First-Line Immunotherapy and Targeted Therapy
Authors: Furkan Bahar, Lauren O’Loughlin, Soravis Osataphan, Hollis Viray, Reed E. Drews, Rushad Patell
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 06:46Neeraj Songara: From Donated Blood to Engineered Therapeutics
-
Sep 20, 2026, 06:24Louise St. Germain Bannon: Improving Awareness and Care for Women Across the Lifespan
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:54William Aird: What Does a Complete History and Physical Really Mean?
-
Sep 20, 2026, 04:34Hons Saurabh Kaushik: Why Uncontrolled LDL Can Be Harmful
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems